The Technical AnalystExchange: PNK Industry: Biotechnology
GeneThera, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0000
America/New_York / 20 feb 2024 @ 13:14
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0000 mill |
| EPS: | -0.0200 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 35.33 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2023-08-15 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0060 - 0.0060 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2011-12-31 | Kolesnikov Avel | Sell | 0 | Common Stock |
| 2012-01-04 | Milici Antonio | Buy | 6 400 000 | Preferred B Stock |
| 2011-12-31 | Irizarry Tannya L | Buy | 2 690 000 | Preferred B Stock |
| 2012-01-04 | Milici Antonio | Buy | 6 400 008 | Preferred B Stock |
| 2008-02-25 | Mcnece Elmer Roy Jr | Buy | 200 000 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 40 transactions |
| Buy: 17 783 008 | Sell: 582 000 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0000 (0.00% ) |
| Volume | 0.0040 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GTHR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GTHR
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company's Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. GeneThera, Inc. is based in Westminster, Colorado.